New daily pill for obesity and diabetes shows promise in early trial
NCT ID NCT05184322
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 32 times
Summary
This early-stage study tested an oral tablet called ecnoglutide in 87 healthy adults to see if it is safe and how the body processes it. The drug is designed to help manage type 2 diabetes and obesity by mimicking a natural hormone that controls blood sugar and appetite. Participants took multiple doses and were monitored for side effects and drug levels in the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Q-Pharm Pty Ltd (AKA Nucleus Network Brisbane)
Herston, Queensland, 4006, Australia
Conditions
Explore the condition pages connected to this study.